<DOC>
	<DOCNO>NCT00461344</DOCNO>
	<brief_summary>Primary : To determine pathological remission follow chemotherapy combination docetaxel doxorubicin large breast cancer Secondary : - Clinical response rate - To investigate safety docetaxel doxorubicin combination treatment neoadjuvant chemotherapy breast cancer - Type surgery ( radical/conservative )</brief_summary>
	<brief_title>Docetaxel + Doxorubicin Neoadjuvant Chemotherapy Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically verify breast cancer Large ( ≥ 3 cm ) breast cancer IIbIIIa stage ECOG ( Eastern Cooperative Oncology Group ) status : 012 Adequate bone marrow reserve : ( Haemoglobin ≥ 12g/l , Absolute Neutrophil Count ( ANC ) ≥ 2.0x 10^9 , Platelets ≥100 000 ) Laboratory result : Bilirubin ≤ Upper Limit Normal ( ULN ) Serum Glutamate Pyruvate Transaminase ( SGPT ) ≤ 2.5 ULN , Serum Glutamate Oxaloacetate Transaminase ( SGOT ) ≤ 2.5 ULN , Alk.phosph . ≤ 5.0 ULN , Creatinin ≤ ULN , borderline calculate ≤ 60ml/min Normal cardiac function ( result Left Ventricular Ejection Function ( LVEF ) must lower limit normal institution ) Negative pregnancy test Hormonal receptor status assess Pregnancy lactation SGOT and/or SGPT &gt; 1.5 upper limit normal , associated Alk.phosph &gt; 2.5 ULN Serious medical condition include limited : Uncontrolled hypertension Active ulcus pepticum Nonstable diabetes mellitus Other contraindication steroid treatment Myocardial infarction within last 6 month prior study entry Significant neurologic/psychiatric disorder Active infection Peripheral neuropathy grade ≥ 2 Unstable angina Severe arrhythmia Participation clinical trial Prior surgery , chemotherapy , hormonotherapy breast cancer Past current history neoplasm breast cancer , except : curatively treat nonmelanoma skin cancer , situ carcinoma cervix , cancer curatively treat evidence disease least 7 year History hypersensitivity investigational product drug similar chemical structure Likelihood require treatment study period drug permit clinical study protocol Treatment investigational product last 1 month study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Breast</keyword>
</DOC>